Surging Demand for Venous Thromboembolism Prevention Devices Fuels Market Expansion

 Venous Thromboembolism Treatment Market is projected to reach $4.40 billion by 2030

Venous thromboembolism (VTE) occurs when blood clots form in the deep veins of the arms or legs and circulate through the bloodstream. This condition impedes blood flow and oxygen delivery, potentially leading to tissue and organ damage. Deep vein thrombosis (DVT) and pulmonary embolism are significant manifestations of VTE, and if left untreated, VTE can be fatal. Various prevention measures, including thrombectomy devices, compression pumps, and stockings, play crucial roles in mitigating the risk. 

Download Complete Sample PDF Copy Here: https://www.meticulousresearch.com/download-sample-report/cp_id=5745 

Recent years have witnessed a notable increase in the utilization of VTE prevention devices. This surge is primarily driven by the high incidence of VTE, the rising prevalence of secondary risk factors associated with vascular diseases, and an increasing demand for minimally invasive treatment options. 

Growing Prevalence of Venous Thromboembolism 

Vascular diseases disrupt blood flow in veins and arteries, with VTE representing a serious health threat due to the formation of blood clots. Deep vein thrombosis occurs when clots obstruct blood flow in deep veins, particularly in the lower legs, thighs, arms, or pelvis. If a clot dislodges, it can travel to the lungs, resulting in pulmonary embolism—a life-threatening condition. According to the American Heart Association, approximately 1,220,000 individuals in the U.S. are affected by VTE annually. 

Despite its prevalence, awareness of VTE remains low, contributing to its status as one of the leading global causes of mortality. In response, governments and organizations are implementing initiatives to increase awareness. For example, the Indian Council of Medical Research (ICMR) launched a National Hospital-based Registry on Venous Thromboembolic Disorders (i-RegVeD) in June 2022 to monitor VTE prevalence. Additionally, the International Society on Thrombosis and Haemostasis (ISTH) conducted a global campaign on October 13, 2023, to promote awareness about thrombosis-related conditions. 

The growth of the VTE treatment market can be attributed to the high prevalence of the condition, the rising incidence of cancer, increasing secondary risk factors such as diabetes and obesity, more orthopedic surgeries, and a heightened demand for minimally invasive treatment procedures. 

Check complete table of contents with list of table and figures: https://www.meticulousresearch.com/product/venous-thromboembolism-treatment-market-5745 

High Growth Potential in Emerging Economies 

Emerging economies, such as India, China, and Brazil, face challenges in ensuring timely prevention and treatment of VTE. A 2022 survey among hematologists in China found that only 27.3% accurately identified risk factors associated with VTE or DVT. Despite these challenges, technological advancements and globalization are facilitating the adoption of advanced VTE prevention technologies. For instance, Wallaby Medical, LLC. launched its pRESET thrombectomy device in Brazil in August 2022, aimed at improving VTE management in local healthcare settings. 

The high prevalence of VTE in these regions is expected to drive demand for VTE treatment and prevention devices, offering significant market opportunities. 

Diagnosis & Prevention of Venous Thromboembolism Through New Technologies 

Recent advancements in the diagnosis, prevention, and management of VTE have been remarkable. Noninvasive imaging, D-dimer testing, and clinical prediction rules have improved the speed and accuracy of VTE diagnosis. The rise of outpatient surgeries, with approximately 9,100 active outpatient surgery centers in the U.S. performing procedures such as colonoscopy, hip replacement, and knee replacement, has highlighted the need for effective products that enable at-home compression therapy to mitigate the risk of DVT. 

Innovative solutions like the Clot Knot device, developed by the Fox Chase Cancer Center, integrate sequential compression devices or stockings into outpatient therapy routines. Intermittent pneumatic compression (IPC) devices are another effective option for preventing blood clots post-surgery. 

Moreover, advances in VTE management now include AI-guided software for diagnosis, significantly improving efficiency. Companies like Viz.ai, Inc. launched AI-powered modules in November 2021 to diagnose pulmonary embolism and aortic disease, utilizing deep learning for rapid identification. 

Insights from the Venous Thromboembolism Treatment Market Analysis 

According to recent insights from Meticulous Research®, the Venous Thromboembolism Treatment Market is projected to reach a worth of $4.40 billion by 2030, with a compound annual growth rate (CAGR) of 7.2% from 2023 to 2030. 

Emerging trends in the VTE treatment market reflect the ongoing evolution of technologies for prevention and treatment, driven by increasing VTE prevalence and a rise in secondary risk factors like diabetes and obesity. 

North America is expected to dominate the market in 2023, with key players such as Boston Scientific Corporation, Stryker Corporation, Cardinal Health, Inc., Enovis Corporation, Medtronic plc, and Cook Group Incorporated playing significant roles in the widespread adoption of VTE prevention devices. 

Conclusion 

The increased focus on VTE prevention, combined with a growing preference for minimally invasive treatments, is driving global adoption of VTE prevention devices. Technological advancements, including portable VTE and DVT prevention solutions, along with AI integration for diagnosis and prevention, are further propelling market growth. Additionally, government initiatives and the launch of innovative VTE prevention devices, including thrombectomy devices, compression pumps, and stockings, are contributing to the overall expansion of the market. 

Buy Now: https://www.meticulousresearch.com/Checkout/32725924 

Contact Us:
Meticulous Market Research Pvt. Ltd.
1267 Willis St, Ste 200 Redding,
California, 96001, U.S.
USA: +1-646-781-8004
Europe : +44-203-868-8738
APAC: +91 744-7780008
Email- sales@meticulousresearch.com
Visit Our Website: https://www.meticulousresearch.com/
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research